Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
Rhea-AI Summary
Celldex Therapeutics (NASDAQ:CLDX) will host a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its Q4 and full year 2021 financial results and corporate updates. Interested parties can access the live or recorded webcast on the company's website. Celldex focuses on developing monoclonal and bispecific antibodies targeting serious diseases with inadequate treatments. Their pipeline aims to enhance patient outcomes in cancer and inflammatory diseases.
Positive
- Potential for positive financial results from Q4 and full year 2021 discussion.
- Company is dedicated to developing innovative antibody-based therapeutics.
Negative
- None.
News Market Reaction – CLDX
In the trading session that priced this news, CLDX declined 3.26%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highlights.
To access a live or recorded webcast of the call, please visit the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (United States) or (760) 298-5103 (international). The conference call passcode is 2177774.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com
